This section provides guidance for companies who are expanding their operations.

GNC 2: Cyber security hygiene for Life Science
GNC 1: Cybersecurity for Life Science business leaders
GNI 1: Cargo Stock Throughput-State of the Market Update
GNMA7: Impact of Brexit on the regulatory approval process for medicines in the UK
GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement
GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe
GNMA 3: How can early access schemes support accelerated patient access in Europe?
GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation
GNMA 1: Improving access to orphan medicines
GNP 12: Patenting New Uses of Old Drugs
GNP 9: Procedural Overview of Seeking Patent Protection Abroad
GNT69: Making Tax Digital for Corporation Tax
GNT68: Making Tax Digital for VAT
GNT 67: Non-resident directors
GNT 65: A tax overview of share schemes and other equity incentives
GNT 64: Off payroll workers : IR35 for the private sector from April 2021
GNT 59: Corporation Tax Deductions for Employee Share Schemes
GNT 58: Corporate Criminal Offence – As Applied to Life Sciences
GNT 54: PAYE Settlement Agreements (PSAs)
GNT 34: Termination Payments
GNT 23: Permanent Establishments
GNT 13: Expansion into New Territories
GNT 11: Transfer Pricing Essentials
GNT 42: Corporation Tax Loss Relief Reform
GNT 38: Bioscience Explained to Support Tax Returns
GNT 29: Tax Model
GNT 17: Compliance Essentials
GNT 6: Tax Framework and Strategy
GNT 47: Patent Box R&D Fraction – As Applied to Life Sciences

Register to receive up-to-date information and advice on tax developments within your industry.